Blue Jet Healthcare Limited has submitted its Analysts/Investors Presentation on Financial Results for the quarter ended September 30, 2026. The presentation highlights Q2 & H1 FY27 earnings, including highest quarterly sales of Rs 3,757 million. Key updates cover R&D facility operations, successful delivery of a new Contrast Media Intermediate, and development of Amino Acid Derivatives.
Blue Jet Healthcare Presents Q2 and H1 FY27 Financials
Blue Jet Healthcare Limited has released its investor presentation detailing the financial results for the second quarter and first half of the financial year 2027, ending September 30, 2026. The company announced its highest quarterly sales to date, reaching Rs 3,757 million in the current quarter.
Key Business Updates
- The R&D center in Hyderabad is now operational with 40 resources on board and actively engaged in activities.
- The company has successfully delivered and validated a new Contrast Media Intermediate to an innovator.
- Blue Jet Healthcare has developed Amino Acid Derivatives for Peptide Fragments, which are slated for commercialization and shipment in Q4 FY27.
Financial Performance Highlights
In Q2 FY27, Revenue from Operations stood at Rs 3,757 million, with EBITDA at Rs 1,188 million (32% Margin) and PAT at Rs 1,025 million (27% Margin). This represents a 28% QoQ increase in revenue and a 21% QoQ increase in EBITDA. Year-on-year, Q2 FY27 revenue saw a significant increase of 127% compared to Q2 FY26, reaching Rs 3,757 million versus Rs 1,655 million. EBITDA increased by 116% YoY.
For the half-year ended H1 FY27, Revenue from Operations was Rs 6,689 million, with EBITDA at Rs 2,168 million (32% Margin) and PAT at Rs 1,808 million (27% Margin). This shows a 29% YoY growth in revenue compared to H1 FY26.
Source: BSE
